These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 4737081)

  • 1. Speech defects of parkinsonian patients. Effects of levodopa therapy on speech intelligibility.
    Nakano KK; Zubick H; Tyler HR
    Neurology; 1973 Aug; 23(8):865-70. PubMed ID: 4737081
    [No Abstract]   [Full Text] [Related]  

  • 2. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):31-5. PubMed ID: 4924342
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
    Klett CJ; Caffey E
    Arch Gen Psychiatry; 1972 Apr; 26(4):374-9. PubMed ID: 4552131
    [No Abstract]   [Full Text] [Related]  

  • 4. [Speech and voice disorders in Parkinson's disease].
    Martnez-Sánchez F
    Rev Neurol; 2010 Nov; 51(9):542-50. PubMed ID: 20979034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders.
    Timberlake WH
    Neurology; 1970 Dec; 20(12):Suppl:31-5. PubMed ID: 4921586
    [No Abstract]   [Full Text] [Related]  

  • 6. Lip muscle function in Parkinsonian Dysarthria.
    Leanderson R; Meyerson BA; Persson A
    Acta Otolaryngol; 1972 Nov; 74(5):350-7. PubMed ID: 4565338
    [No Abstract]   [Full Text] [Related]  

  • 7. Levodopa in Parkinson's disease: effect on pulmonary function.
    Nakano KK; Bass H; Tyler HR
    Arch Intern Med; 1972 Sep; 130(3):346-8. PubMed ID: 4560177
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of speech therapy and pharmacological treatment in prosody of parkinsonians.
    Azevedo LL; Souza IS; Oliveira PM; Cardoso F
    Arq Neuropsiquiatr; 2015 Jan; 73(1):30-5. PubMed ID: 25608124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential changes in motor speech across a levodopa cycle in advanced Parkinson's disease.
    De Letter M; Van Borsel J; Boon P; De Bodt M; Dhooge I; Santens P
    Int J Speech Lang Pathol; 2010 Oct; 12(5):405-13. PubMed ID: 20602581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dosage chlorpromazine alone and in combination with an antiparkinsonian agent (procyclidine) in the treatment of hospitalized depressions.
    Raskin A
    J Nerv Ment Dis; 1968 Aug; 147(2):184-95. PubMed ID: 4877904
    [No Abstract]   [Full Text] [Related]  

  • 11. For better or worse: The effect of levodopa on speech in Parkinson's disease.
    Ho AK; Bradshaw JL; Iansek R
    Mov Disord; 2008 Mar; 23(4):574-80. PubMed ID: 18163453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polar-phase indices of perioral muscle reciprocity during syllable production in Parkinson's disease.
    Chu SY; Barlow SM; Lee J; Wang J
    Int J Speech Lang Pathol; 2017 Dec; 19(6):616-627. PubMed ID: 28425760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prosodic expression and levodopa in Parkinson's disease.
    Behlau M
    Arq Neuropsiquiatr; 2013 Nov; 71(11):831-2. PubMed ID: 24394865
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy.
    Rusz J; Cmejla R; Růžičková H; Klempíř J; Majerová V; Picmausová J; Roth J; Růžička E
    J Neural Transm (Vienna); 2013 Feb; 120(2):319-29. PubMed ID: 22772465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa-induced alterations in speech rate in advanced Parkinson's disease.
    De Letter M; Santens P; De Bodt M; Boon P; Van Borsel J
    Acta Neurol Belg; 2006 Mar; 106(1):19-22. PubMed ID: 16776432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism.
    Mindham RH; Lamb P; Bradley R
    Br J Psychiatry; 1977 Jun; 130():581-5. PubMed ID: 326325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kr 339 in the treatment of parkinsonian tremor].
    Iivanainen M
    Duodecim; 1974; 90(8):590-6. PubMed ID: 4605767
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of fusaric acid in Parkinson's disease.
    Herskovits E; Figueroa Gacitua E
    Medicina (B Aires); 1973; 33(1):51-8. PubMed ID: 4573120
    [No Abstract]   [Full Text] [Related]  

  • 19. The clinical use of levodopa in the treatment of Parkinson's disease.
    McDowell FH; Markham CH; Lee JE; Treciokas LJ; Ansel RD
    Contemp Neurol Ser; 1971; 8():175-201. PubMed ID: 4950056
    [No Abstract]   [Full Text] [Related]  

  • 20. KR 339 in the treatment of Parkinsonian tremor.
    Iivanainen M
    Acta Neurol Scand; 1974; 50(4):469-77. PubMed ID: 4604665
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.